Literature DB >> 26568781

Diagnosis and Management of Polycythemia Vera: Proceedings from a Multidisciplinary Roundtable.

Lisa A Raedler.   

Abstract

Entities:  

Year:  2014        PMID： 26568781      PMCID： PMC4639938     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  58 in total

Review 1.  Polycythemia vera: myths, mechanisms, and management.

Authors:  Jerry L Spivak
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

2.  Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera.

Authors:  Alberto Alvarez-Larrán; Arturo Pereira; Francisco Cervantes; Eduardo Arellano-Rodrigo; Juan-Carlos Hernández-Boluda; Francisca Ferrer-Marín; Anna Angona; Montse Gómez; Begoña Muiña; Helga Guillén; Anabel Teruel; Beatriz Bellosillo; Carmen Burgaleta; Vicente Vicente; Carles Besses
Journal:  Blood       Date:  2011-12-12       Impact factor: 22.113

3.  Masked polycythemia vera (mPV): results of an international study.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Guido Finazzi; Alessandra Carobbio; Elisa Rumi; Maria Luigia Randi; Irene Bertozzi; Alessandro M Vannucchi; Lisa Pieri; Valentina Carrai; Bettina Gisslinger; Leonhard Müllauer; Marco Ruggeri; Alessandro Rambaldi; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2013-09-19       Impact factor: 10.047

4.  Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.

Authors:  Y Najean; J D Rain
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

Review 5.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

6.  Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations.

Authors:  Alessandro M Vannucchi; Paola Guglielmelli
Journal:  Haematologica       Date:  2008-07       Impact factor: 9.941

Review 7.  Thrombotic disease in the myeloproliferative neoplasms.

Authors:  Anna Falanga; Marina Marchetti
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

8.  The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.

Authors:  Robyn Scherber; Amylou C Dueck; Peter Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Francesco Passamonti; Bjorn Andreasson; Maria L Ferarri; Alessandro Rambaldi; Jan Samuelsson; Gunnar Birgegard; Ayalew Tefferi; Claire N Harrison; Deepti Radia; Ruben A Mesa
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

9.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.

Authors:  Francesco Passamonti; Margherita Maffioli; Domenica Caramazza; Mario Cazzola
Journal:  Oncotarget       Date:  2011-06
View more
  4 in total

1.  Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study.

Authors:  Michael R Grunwald; John M Burke; David J Kuter; Aaron T Gerds; Brady Stein; Mark A Walshauser; Shreekant Parasuraman; Philomena Colucci; Dilan Paranagama; Michael R Savona; Ruben Mesa
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-06-13

Review 2.  Ruxolitinib in Myelofibrosis and Polycythemia Vera.

Authors:  Leah Wolfe
Journal:  J Adv Pract Oncol       Date:  2016-05-01

3.  Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report.

Authors:  Rime Benmalek; Hanane Mechal; Hatim Zahidi; Karim Mounaouir; Salim Arous; Mohamed El Ghali Benouna; Abdenasser Drighil; Rachida Habbal
Journal:  J Med Case Rep       Date:  2021-02-16

Review 4.  Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.

Authors:  Ruth Stuckey; María Teresa Gómez-Casares
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.